[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100094624":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":25,"locations":33,"responsibleParty":46,"collaborators":25,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":25,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":25,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":71,"whyStopped":72,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Hospira, now a wholly owned subsidiary of Pfizer","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A","EXPERIMENTAL","PMI-150 (intranasal ketamine)",[13],"Drug: PMI-150 (intranasal ketamine)",{"label":15,"type":16,"description":17,"interventionNames":18},"B","PLACEBO_COMPARATOR","placebo",[19],"Drug: placebo",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","intranasal dosing",[9],null,{"type":22,"name":17,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Zahid Bajwa, MD","Beth Israel Deaconess Medical Center","PRINCIPAL_INVESTIGATOR",[34],{"facility":31,"status":25,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":25},"Boston","Massachusetts","02115","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},{"type":47,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100094624","phase-3-safety-and-efficacy-of-pmi-150-intranasal-ketamine-for-the-treatment-of-breakthrough-pain-in-cancer-patients-100094624",false,"NCT00492388","Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients","Inclusion Criteria:\n\n* at least 18 years of age\n* Patients requiring around-the-clock opioids for pain due to cancer and with a history of experiencing episodes of breakthrough pain\n\nExclusion Criteria:\n\n* under 18 years\n* non-cancer pain\n* allergy to ketamine","ALL","18 Years",{"count":58,"type":59},2,"ACTUAL","INTERVENTIONAL",[62],"PHASE3","To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.",[65,66],"Pain","Cancer",[68,69,70],"breakthrough","pain","cancer","TERMINATED","Business decision not to continue development","2012-01-10",{"date":75,"type":76},"2012-01-11","ESTIMATED",{"date":78,"type":25},"2007-06",{"date":80,"type":59},"2011-08",{"name":5,"class":6},1]